Structure Therapeutics shares are trading lower. The company announced clinical trial results from its oral small molecule amylin and GLP-1 programs for chronic weight management.

Benzinga Newsdesk www.benzinga.com Neutral 51.7%

Neg 0% Neu 51.7% Pos 0%

Comments

No comments yet. Be the first!